These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26885037)

  • 1. Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.
    Li X; Jie Y; You X; Shi H; Zhang M; Wu Y; Lin G; Li X; Gao Z; Chong Y
    Int J Clin Exp Med; 2015; 8(11):21062-70. PubMed ID: 26885037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
    Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
    [No Abstract]   [Full Text] [Related]  

  • 4. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
    J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients].
    Yu JH; Shi JP; Wu J; Li XO; Guo JC; Xun YH; Zhao C; Jin J; Xu AF; Lou GQ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Feb; 19(2):88-92. PubMed ID: 21492508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
    Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
    Liu F; Wang X; Wei F; Hu H; Zhang D; Hu P; Ren H
    Virol J; 2014 Mar; 11():59. PubMed ID: 24673792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
    Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
    Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
    Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2941-7. PubMed ID: 22430972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.